PRECLINICAL TOXICOLOGICAL TESTING AND SAFEGUARDS IN CLINICAL TRIALSGRAHAME SMITH DG.1982; EUR. J. CLIN. PHARMACOL.; ISSN 0031-6970; DEU; DA. 1982; VOL. 22; NO 1; PP. 1-6Article

SYMPOSIUM "MOXALACTAM": EXPERIENCE FRANCAISE, EVALUATION PRE-CLINIQUE ET THERAPEUTIQUE, PARIS, LE 27 OCTOBRE 19811983; SEMAINE DES HOPITAUX; ISSN 0037-1777; FRA; DA. 1983; VOL. 59; NO 26; PP. 1943-2004; ABS. ENG; BIBL. DISSEM.Conference Paper

MEDICAMENTS NOUVEAUX ET EXPERIMENTATION ANIMALECIER A.1982; S.T.A.L.; ISSN 0339-722X; FRA; DA. 1982; VOL. 7; NO 4; PP. 311-314; ABS. ENG; BIBL. 7 REF.Article

CHINICAL COMPARISON OF THE NITROSOUREAS.WASSERMAN TH; SLAVIK M; CARTER SK et al.1975; CANCER; U.S.A.; DA. 1975; VOL. 36; NO 4; PP. 1258-1268; BIBL. 2 P. 1/2Article

IN VITRO ASSAYS IN PRECLINICAL ANTINEOPLASTIC DRUG SCREENINGWEISENTHAL LM.1981; SEMIN. ONCOL.; ISSN 0093-7754; USA; DA. 1981; VOL. 8; NO 4; PP. 362-376; BIBL. 149 REF.Article

Technetium-99m galactosyl-neoglycoalbumin: preparation and preclinical studiesVERA, V. R; STADALNIK, R. C; KROHN, K. A et al.Journal of nuclear medicine. 1985, Vol 26, Num 10, pp 1157-1167, issn 0097-9058Article

ACRIDONE ALKALOIDS: EXPERIMENTAL ANTITUMOR ACTIVITY OF ACRONYCINEGERZON K; SVOBODA GH.1983; ALKALOIDS; ISSN 0099-9598; USA; DA. 1983; VOL. 21; PP. 1-28; BIBL. 80 REF.Article

TOXICOLOGY OF AMSA IN BEAGLE DOGS AND CDF₁ MICEPAVKOV KL; THAKE DC.1982; CANCER TREAT. REP.; ISSN 0361-5960; USA; DA. 1982; VOL. 66; NO 11; PP. 1939-1943; BIBL. 10 REF.Article

COMPARISON OF THE REINFORCING PROPERTIES OF COCAINE AND PROCAINE IN RHESUS MONKEYSJOHANSON CE; AIGNER T.1981; PHARMACOL., BIOCHEM. BEHAV.; ISSN 0091-3057; USA; DA. 1981; VOL. 15; NO 1; PP. 49-53; BIBL. 23 REF.Article

Strategies for improving drug development in the early phaseGRIGOLEIT, H.-G.Pharmazeutische Industrie. 1984, Vol 46, Num 5, pp 521-525, issn 0031-711XArticle

Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directionsVENDITTI, J. M; WESLEY, R. A; PLOWMAN, J et al.Advances in pharmacology and chemotherapy. 1984, Vol 20, pp 1-20, issn 0065-3144Article

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441YAN ZHAO; THOMAS, Huw D; BATEY, Michael A et al.Cancer research (Baltimore). 2006, Vol 66, Num 10, pp 5354-5362, issn 0008-5472, 9 p.Article

The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiersTALMADGE, J. E; HERBERMAN, R. B.Cancer treatment reports. 1986, Vol 70, Num 1, pp 171-182, issn 0361-5960Article

The preclinical new drug research program of the National Cancer Institute = Le programme de recherche préclinique de nouveaux produits du National Cancer InstituteDRISCOLL, J. S.Cancer treatment reports. 1984, Vol 68, Num 1, pp 63-76, issn 0361-5960Article

Regulatory considerations on the role of general pharmacology studies in the development of therapeutic agentsPROAKIS, A. G.Drug development research. 1994, Vol 32, Num 4, pp 233-236, issn 0272-4391Conference Paper

Etoposide (VP-16-213). Current status of an active anticancer drugÓDWYER, P. J; LEYLAND-JONES, B; ALONSO, M. T et al.The New England journal of medicine. 1985, Vol 312, Num 11, pp 692-700, issn 0028-4793Article

Preclinical restenosis models : Challenges and successesTOUCHARD, Arturo G; SCHWARTZ, Robert S.Toxicologic pathology. 2006, Vol 34, Num 1, pp 11-18, issn 0192-6233, 8 p.Conference Paper

Unresolved issues in combination chemotherapyWITTES, R. E; GOLDIN, A.Cancer treatment reports. 1986, Vol 70, Num 1, pp 105-125, issn 0361-5960Article

Antihyperlipidemic properties of β-pyridylcarbinol. A review of preclinical studiesCOHEN, M.Life sciences (1973). 1985, Vol 37, Num 21, pp 1949-1961, issn 0024-3205Article

Preclinical predictors of clinical safety : Opportunities for improvementSISTARE, F. D; DEGEORGE, J. J.Clinical pharmacology and therapeutics. 2007, Vol 82, Num 2, pp 210-214, issn 0009-9236, 5 p.Article

Abstracts/Research Society on Alcoholism meeting, June 1-5, 1988, Charleston, SC, USAAlcoholism, clinical and experimental research. 1988, Vol 12, Num 2, pp 302-348, issn 0145-6008Conference Proceedings

Preclinical pharmacokinetics of benznidazoleWORKMAN, P; WHITE, R. A. S; WALTON, M. I et al.British journal of cancer. 1984, Vol 50, Num 3, pp 291-303, issn 0007-0920Article

4'-EPI-DOXORUBICIN, A NEW ANALOGUE OF DOXORUBICIN: A PRELIMINARY OVERVIEW OF PRECLINICAL AND CLINICAL DATA = LA 4'-EPI-DOXORUBICINE, UN NOUVEL ANALOGUE DE L'ADRIAMYCINE: REVUE PRELIMINAIRE DES DONNEES CLINIQUES ET EXPERIMENTALESGANZINA F.1983; CANCER TREATMENT REVIEWS; ISSN 0305-7372; GBR; DA. 1983; VOL. 10; NO 1; PP. 1-22; ABS. ENG; BIBL. 68 REF.Article

HIGH - DOSE THERAPY WITH FTORAFUR IN GASTROINTESTINAL CANCERKLEIN HO; WICKRAMANAYAKE PD; VOIGTMANN R et al.1981; RECENT RESULTS CANCER RES.; ISSN 0080-0015; USA; DA. 1981; VOL. 79; PP. 65-81; BIBL. 52 REF.Conference Paper

CLINICAL EVALUATION OF LONG-TERM, CONTINUOUS-INFUSION DOXORUBICIN = ETUDE CLINIQUE DE L'ADRIAMYCINE EN PERFUSION CONTINUE A LONG TERMEGARNICK MB; WEISS GR; STEELE GD JR et al.1983; CANCER TREATMENT REPORTS; ISSN 0361-5960; USA; DA. 1983; VOL. 67; NO 2; PP. 133-142; ABS. ENG; BIBL. 20 REF.; GRAPH, FIGArticle